February 22, 2018 / 6:21 AM / 10 months ago

BRIEF-Ablynx FY Operating Loss Widens To 54.2‍​ Million Euros

Feb 22 (Reuters) - ABLYNX NV:

* FY OPERATING LOSS OF EUR 54.2‍​ MILLION VERSUS LOSS OF EUR 28.6 MILLION YEAR AGO

* FY NET LOSS OF EUR 108.5‍​ MILLION VERSUS LOSS OF EUR 1.1 MILLION YEAR AGO

* CASH POSITION AT DEC 31 EUR 354.3‍​ MILLION VERSUS EUR 235.4 MILLION YEAR AGO

* FY TOTAL REVENUE AND GRANT INCOME EUR ‍​55.5 MILLION VERSUS EUR 85.2 MILLION YEAR AGO

* MAY RECEIVE MARKETING AUTHORISATION FOR CAPLACIZUMAB IN ATTP IN Q3 2018

* FOR ALX-0171, A PHASE II STUDY TO BE INITIATED IN H1 2018

* RESULTS FROM ONGOING ALX-0171 PHASE IIB STUDY IN RSV-INFECTED HOSPITALISED INFANTS ARE EXPECTED IN Q4 2018

* PHASE II RESULTS FOR VOBARILIZUMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS EXPECTED IN H1 2018

* EXPECTS UP TO THREE NANOBODIES TO ENTER PHASE I STUDIES FROM OUR COLLABORATIVE PROGRAMMES DURING 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below